GT Biopharma

Temozolomide (GTM-105) is an oral small-molecule antineoplastic agent in Phase 3 development by GT Biopharma for glioblastoma, a highly aggressive primary brain tumor with poor prognosis. The drug is a DNA-alkylating agent administered orally and belongs to the therapeutic class of antineoplastic and immunomodulating agents (L01). GT Biopharma is advancing the program through pivotal Phase 3 clinical testing, with a latest disclosed milestone dated 30 April 2026. Temozolomide has an extensive regulatory history: it is approved in the United States, European Union, and Australia under multiple manufacturers including Merck Sharp & Dohme, Accord Healthcare, Sandoz, and others. The drug is marketed under the brand APO-TEMOZOLOMIDE and carries multiple PBS codes in Australia, reflecting its established clinical role. The current Phase 3 program (NCT07195591) represents GT Biopharma's strategy to advance or expand the therapeutic application in glioblastoma. No mechanism of action, specific target, or peak sales projections have been disclosed. The program remains active with an expected next milestone not yet publicly announced.

Glioblastoma (WHO Grade IV) remains one of the most lethal human malignancies, with median overall survival of approximately 12–15 months despite multimodal therapy including surgery, radiation, and chemotherapy. The standard-of-care regimen has incorporated temozolomide since the early 2000s, yet outcomes remain poor and recurrence is nearly universal. Unmet medical needs persist in improving efficacy, tolerability, and overcoming acquired resistance. Temozolomide's established safety and efficacy profile, combined with oral bioavailability, make it a foundational agent; however, the Phase 3 program by GT Biopharma suggests investigation of a novel formulation, dosing strategy, or combination approach to enhance clinical benefit. The competitive landscape includes multiple approved antineoplastic agents (Imbruvica, Afinitor, Kyprolis, Vyxeos Liposomal, and others), though few are specifically optimized for glioblastoma. The patient population for glioblastoma is limited but critically underserved; any advancement in efficacy or tolerability could have significant clinical impact. Commercial relevance is moderate given the rarity of glioblastoma but substantial given the high unmet need and the potential for label expansion or improved formulation in a disease with high mortality and morbidity.

Drug Class: Antineoplastic and immunomodulating agent (ATC L01).

Modality: Small-molecule oral formulation.

Route of Administration: Oral.

Brand Name: APO-TEMOZOLOMIDE.

Mechanism of Action: Not yet disclosed in the program documentation; however, temozolomide is a DNA-alkylating agent that methylates DNA at the O6 and N7 positions of guanine, leading to DNA strand breaks and apoptosis.

Target: Not yet disclosed.

Related Therapies: Temozolomide is the foundational chemotherapy for glioblastoma, typically combined with radiotherapy and followed by adjuvant monotherapy. Other antineoplastic agents in the competitive space include Imbruvica (ibrutinib), Afinitor (everolimus), Kyprolis (carfilzomib), and Vyxeos Liposomal (daunorubicin/cytarabine), though these are not glioblastoma-specific.

First Approval: Temozolomide was first approved in Australia on 1 February 2000 and in the United States under NDA021029. Multiple generic and branded versions are now approved globally.

Patent Status: Not disclosed; however, the active pharmaceutical ingredient temozolomide is off-patent, with multiple approved generic manufacturers.

United States (FDA): Temozolomide is approved under NDA021029 and NDA022277. Multiple generic versions are approved under ANDAs (ANDA078879, ANDA201528, ANDA201742, ANDA203490, ANDA203691, ANDA203898, ANDA203959, ANDA204159, ANDA204639, ANDA205227, ANDA206309, ANDA206413, ANDA206750, ANDA207658, ANDA210030, ANDA213328) from sponsors including Accord Healthcare, Amneal Pharmaceuticals, Ani Pharmaceuticals, Apotex, Chartwell, Chemi SPA, Deva Holding, Eirgen, Extrovis, Heritage, Hetero Labs, Merck Sharp & Dohme, Nivagen Pharmaceuticals, Rising, Sun Pharma, Watson Labs/Teva, and Zydus Pharmaceuticals.

European Union (EMA): Temozolomide is approved under multiple EMA product numbers (EMEA/H/C/000229, EMEA/H/C/001124, EMEA/H/C/001125, EMEA/H/C/001126, EMEA/H/C/001127, EMEA/H/C/001128, EMEA/H/C/002198, EMEA/H/C/006169) from marketing authorization holders including Accord Healthcare S.L.U., Hexal AG, Merck Sharp & Dohme B.V., ORPHELIA Pharma, Sandoz GmbH, Sun Pharmaceutical Industries Europe B.V., Teva B.V., and medac Gesellschaft für klinische Spezialprodukte mbH. Authorisation dates include 2 May 2025, 10 July 2025, and 6 November 2025.

Australia (TGA): Temozolomide is approved under multiple PBS codes (10062N, 2438H, 8378Y, 8379B, 8380C, 8381D, 8819E, 8820F, 8821G, 9361Q) from sponsors including Alphapharm Pty Ltd, Apotex Pty Ltd, Juno Pharmaceuticals Pty Ltd, and Merck Sharp & Dohme (Australia) Pty Ltd. First listed dates include 1 February 2000, 1 June 2005, and 1 January 2009.

China (NMPA): Temozolomide is in clinical trials in China (NCT05457829); regulatory approval status not yet disclosed.

Japan (PMDA): Regulatory status not yet disclosed.

Strategic Positioning: GT Biopharma's Phase 3 program (GTM-105) with temozolomide in glioblastoma represents a strategy to advance a well-established drug in an indication with high unmet medical need. The use of a generic active pharmaceutical ingredient suggests GT Biopharma may be developing a novel formulation, combination therapy, or optimized dosing regimen rather than a de novo chemical entity. This approach reduces development risk while targeting a disease with poor prognosis and limited therapeutic options.

Competitive Implications: Temozolomide is the standard-of-care backbone for glioblastoma; GT Biopharma's Phase 3 program is unlikely to displace this role but may enhance efficacy, tolerability, or convenience. The competitive landscape for glioblastoma is limited, with few agents specifically approved for this indication. Success in Phase 3 could result in label expansion, improved formulation approval, or combination indication approval, strengthening GT Biopharma's position in oncology.

Future Catalysts: Key catalysts include Phase 3 trial readout (expected milestone not yet disclosed), regulatory submissions to FDA, EMA, and other agencies, and potential label expansion or approval announcements. The latest disclosed milestone (30 April 2026) suggests trial data may be available in mid-2026 or later.

Regulatory and Commercial Outlook: Temozolomide's established safety and efficacy profile, combined with multiple approved generic versions, provides a strong foundation for GT Biopharma's program. However, the commercial opportunity is limited by the rarity of glioblastoma and the established generic market. Success will depend on demonstrating clinically meaningful improvements over current standard of care and securing favorable regulatory pathways (e.g., accelerated approval, breakthrough therapy designation if applicable).